5 active not recruiting, 3 recruiting, 1 withdrawn. 7 Phase 2, 4 Phase 1, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 7 | Active not recruiting 4, Recruiting 2, Withdrawn 1 |
| Phase 1 | 4 | Active not recruiting 2, Recruiting 1, Withdrawn 1 |
| Phase 3 | 1 | Active not recruiting 1 |
Follow Recurrent Ovarian Clear Cell Adenocarcinoma: new trials by email Literature Review of Recurrent Ovarian Clear Cell Adenocarcinoma trials Research Report on Recurrent Ovarian Clear Cell Adenocarcinoma
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Sacituzumab Tirumotecan +/- Pembrolizumab in I/O Exposed Metastatic or Recurrent Ovarian Clear Cell Cancer Sacituzumab tirumotecan, Pembrolizumab - Ovarian Clear Cell Carcinoma, Metastatic Ovarian Cancer | Phase 2 | Recruiting | Tufts Medical Center | 50 | 2026-09-01 | 2026-09-16 |
| Testing the Addition of ASTX660 (Tolinapant) to the Usual Chemotherapy Treatment (Paclitaxel With or Without Bevacizumab) in Patients With Recurrent Ovarian Cancer Bevacizumab, Biospecimen Collection, Computed Tomography - Platinum-Refractory Fallopian Tube Carcinoma, Platinum-Refractory Ovarian Carcinoma | Phase 1 / Phase 2 | Withdrawn | National Cancer Institute (NCI) | 2025-10-31 | 2025-06-03 | |
| Pembrolizumab Combined With Bevacizumab With or Without Agonist Anti-CD40 CDX-1140 for the Treatment of Patients With Recurrent Ovarian Cancer Anti-CD40 Agonist Monoclonal Antibody CDX-1140, Bevacizumab, Pembrolizumab - Ovarian Clear Cell Adenocarcinoma, Platinum-Sensitive Ovarian Carcinoma | Phase 2 | Recruiting | Roswell Park Cancer Institute | 80 | 2024-03-12 | 2026-08-14 |
| Testing Different Amounts of the Combination of Drugs M1774 and ZEN-3694 for the Treatment of Recurrent Ovarian and Endometrial Cancer BET Bromodomain Inhibitor ZEN-3694, Biopsy Procedure, Biospecimen Collection - Recurrent Endometrial Carcinoma, Recurrent Endometrial Clear Cell Adenocarcinoma | Phase 1 | Recruiting | National Cancer Institute (NCI) | 65 | 2023-12-18 | 2026-10-21 |
| Vaccine Therapy Plus Pembrolizumab in Treating Advanced Ovarian, Fallopian Tube, or Primary Peritoneal Cavity Cancer Biopsy, Biospecimen Collection, Computed Tomography - Fallopian Tube Carcinosarcoma, Primary Peritoneal Carcinosarcoma | Phase 1 / Phase 2 | Active not recruiting | Mayo Clinic | 38 | 2023-09-28 | 2026-09-21 |
| Comparison of Standard of Care Treatment With a Triplet Combination of Targeted Immunotherapeutic Agents Biospecimen Collection, Cediranib Maleate, Computed Tomography - Fallopian Tube Mucinous Adenocarcinoma, Ovarian Seromucinous Carcinoma | Phase 2 | Active not recruiting | National Cancer Institute (NCI) | 120 | 2021-06-10 | 2026-10-22 |
| A Study Combining the Peposertib (M3814) Pill With Standard Chemotherapy in Patients With Ovarian Cancer With an Expansion in High Grade Serous Ovarian Cancer and Low Grade Serous Ovarian Cancer Biospecimen Collection, Computed Tomography, Echocardiography Test - Endometrial High Grade Endometrioid Adenocarcinoma, Fallopian Tube Clear Cell Adenocarcinoma | Phase 1 | Active not recruiting | National Cancer Institute (NCI) | 55 | 2020-05-07 | 2026-07-20 |
| Tazemetostat in Treating Patients With Recurrent Ovarian or Endometrial Cancer Computed Tomography, Magnetic Resonance Imaging, Tazemetostat - Recurrent Endometrial Endometrioid Adenocarcinoma, Recurrent Malignant Uterine Corpus Neoplasm | Phase 2 | Active not recruiting | National Cancer Institute (NCI) | 62 | 2019-05-01 | 2026-10-22 |
| Pegylated Liposomal Doxorubicin Hydrochloride With Atezolizumab and/or Bevacizumab in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Atezolizumab, Bevacizumab, Computed Tomography - Fallopian Tube High Grade Serous Adenocarcinoma, Ovarian High Grade Serous Adenocarcinoma | Phase 2 / Phase 3 | Active not recruiting | National Cancer Institute (NCI) | 444 | 2017-06-23 | 2026-10-22 |
Ovarian Neoplasms (6) · Fallopian Tube Neoplasms (4) · Adenocarcinoma, Clear Cell (1) · Endometrial Neoplasms (1) · Neoplasms (1)
Female Urogenital Diseases (7) · Female Urogenital Diseases and Pregnancy Complications (7) · Genital Diseases (7) · Genital Diseases, Female (7) · Genital Neoplasms, Female (7) · Neoplasms by Site (7) · Urogenital Diseases (7) · Urogenital Neoplasms (7) · Adnexal Diseases (6) · Endocrine Gland Neoplasms (6) · Endocrine System Diseases (6) · Gonadal Disorders (6) · Neoplasms (6) · Ovarian Diseases (6) · Fallopian Tube Diseases (4)
Magnetic Resonance Spectroscopy (6) · Specimen Handling (5) · Disulfides (4) · Immunoglobulin G (4) · Bevacizumab (3) · Doxorubicin (3) · liposomal doxorubicin (3) · pembrolizumab (3) · Biopsy (2) · Paclitaxel (2) · Taxes (2) · ASTX-660 (1) · Blood Component Removal (1) · Contrast Media (1) · Phantoms, Imaging (1)
National Cancer Institute (NCI) (6) · Mayo Clinic (1) · Roswell Park Cancer Institute (1) · Tufts Medical Center (1)
United States (8) · Puerto Rico (2)
Emese Zsiros (1) · Fiona Simpkins (1) · Jung-min Lee (1) · Kristen P Zeligs (1) · Matthew S. Block, MD, PhD (1) · Rachel N Grisham (1) · Ramez N Eskander (1) · Roisin E O'Cearbhaill (1)
U10CA180868 (5), R01CA276313 (1), UM1CA186691 (1)